NLS Pharmaceutics News

NLS Pharmaceutics Analyst Ratings

BenzingaSep 14, 2023 07:58 ET

NLS Pharmaceutics (NLSP) Receives a Buy From Maxim Group

TipRanksJun 15, 2023 14:55 ET

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Fate Therapeutics (FATE) and NLS Pharmaceutics (NLSP)

TipRanksMay 4, 2023 07:55 ET

Maxim Group Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)

TipRanksMar 28, 2023 14:56 ET

Maxim Group Keeps Their Buy Rating on NLS Pharmaceutics (NLSP)

TipRanksJan 31, 2023 12:20 ET

Maxim Group Reaffirms Their Buy Rating on NLS Pharmaceutics (NLSP)

TipRanksJan 24, 2023 12:30 ET

NLS Pharmaceutics Analyst Ratings

Benzinga Analyst RatingsDec 8, 2022 08:42 ET

Maxim Group Upgrades NLS Pharmaceutics to Buy, Announces $4 Price Target

Benzinga Real-time NewsDec 8, 2022 08:42 ET

NLS Pharmaceutics Analyst Ratings

Benzinga Analyst RatingsNov 8, 2022 09:02 ET

NLS Pharmaceutics Initiated at Buy by Laidlaw & Co.

Dow JonesSep 6, 2022 10:03 ET

NLS Pharmaceutics Analyst Ratings

Benzinga Analyst RatingsSep 6, 2022 09:53 ET

Laidlaw Starts NLS Pharmaceutics at Buy With $6 Price Target

MT NewswiresSep 6, 2022 06:44 ET